Loading stock data…
$11.89+0.38 (+3.30%)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.21M↑ | $602,000↑ | $419,000 | — | $1.75M |
| Gross Profit | $2.21M↑ | $602,000↑ | $419,000 | — | $1.75M |
| Operating Income | -$150.10M↓ | -$123.84M↑ | -$133.71M | — | -$111.17M |
| Net Income | -$142.84M↓ | -$108.62M↑ | -$137.10M | — | -$115.36M |
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 recepto...